Press Releases

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation...

Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in...

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and...

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ)...